Free for academic non-profit institutions. Other users need a Commercial license
The protein encoded by this gene is a member of the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. This kinase is activated by various environmental stresses and proinflammatory cytokines. The activation requires its phosphorylation by MAP kinase kinases (MKKs), or its autophosphorylation triggered by the interaction of MAP3K7IP1/TAB1 protein with this kinase. The substrates of this kinase include transcription regulator ATF2, MEF2C, and MAX, cell cycle regulator CDC25B, and tumor suppressor p53, which suggest the roles of this kinase in stress related transcription and cell cycle regulation, as well as in genotoxic stress response. Four alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]
MAPK14 (Mitogen-Activated Protein Kinase 14) is a Protein Coding gene. Diseases associated with MAPK14 include Chlamydia and Inflammatory Bowel Disease 15. Among its related pathways are ATM Pathway and Monoamine Transport. Gene Ontology (GO) annotations related to this gene include transferase activity, transferring phosphorus-containing groups and protein tyrosine kinase activity. An important paralog of this gene is MAPK11.
MAPKs (mitogen-activated protein kinases) are serine-threonine kinases that regulate a wide variety of cellular functions.
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000166 | nucleotide binding | IEA | -- |
GO:0004672 | protein kinase activity | IEA | -- |
GO:0004674 | protein serine/threonine kinase activity | IEA,TAS | -- |
GO:0004707 | MAP kinase activity | IEA,IDA | 7997261 |
GO:0004708 | MAP kinase kinase activity | TAS | 10706854 |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000922 | spindle pole | IEA | -- |
GO:0005576 | extracellular region | TAS | -- |
GO:0005623 | cell | IEA | -- |
GO:0005634 | nucleus | IBA,ISS | -- |
GO:0005654 | nucleoplasm | TAS | -- |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | Activated TLR4 signalling | ||
2 | IL-2 Pathway |
ErbB Family Pathway
.59
ErbB4 Pathway
.59
Prolactin Signaling
.54
Growth Hormone Signaling
.49
IL-2 Pathway
.48
|
LPS Stimulated MAPK Signaling
.47
UVC-Induced MAPK Signaling
.44
TREM1 Pathway
.43
HMGB1 Pathway
.36
PI3K Signaling in B-Lymphocyte
.35
|
3 | Toll-Like receptor Signaling Pathways |
Mucin expression in CF via TLRs, EGFR signaling pathways
.42
Immune response IL-1 signaling pathway
.41
|
|
4 | 4-1BB Pathway |
4-1BB Pathway
.54
CD40 Signaling
.54
CMV and MAPK Pathways
.46
|
NF-KappaB Activation by EBV
.42
PKR Pathway
.36
SUMO Pathway
.30
|
5 | G-protein signaling Ras family GTPases in kinase cascades (scheme) |
G-protein signaling Ras family GTPases in kinase cascades (scheme)
.44
.44
Immune response Oncostatin M signaling via MAPK in human cells
.39
|
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000077 | DNA damage checkpoint | IEA | -- |
GO:0000165 | MAPK cascade | IEA | -- |
GO:0000187 | activation of MAPK activity | TAS | -- |
GO:0000902 | cell morphogenesis | IEA | -- |
GO:0001502 | cartilage condensation | IEA | -- |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
Minocycline | Approved, Investigational | Pharma | Target, inhibitor | 229 | ||
Dasatinib | Approved, Investigational | Pharma | Target | Kinase Inhibitors, SRC/BCR-ABL tyrosine kinase inhibitors | 324 | |
fostamatinib | Approved, Investigational | Pharma | Target, inhibitor | Kinase Inhibitors | 0 | |
Pirfenidone | Approved, Investigational | Pharma | inhibitor | TGF-β production inhibitor, Antifibrotic agent; regulates cytokine levels in vivo | 86 | |
Magnesium | Approved, Experimental, Investigational | Pharma | 0 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs | |
---|---|---|---|---|---|---|
ADP |
|
Agonist, Full agonist, Partial agonist, Gating inhibitor, Antagonist | 58-64-0 |
|
Compound | Action | Cas Number |
---|---|---|
CMPD-1 | Selective inhibitor of p38alpha-mediated MK2a phosphorylation; also tubulin polymerization inhibitor | 41179-33-3 |
SKF 86002 dihydrochloride | p38 MAPK inhibitor; anti-inflammatory agent | 116339-68-5 |
TAK 715 | Potent p38 MAPK inhibitor; anti-inflammatory | 303162-79-0 |
Compound | Action | Cas Number |
---|---|---|
AL 8697 | p38α inhibitor,potent and selective | 1057394-06-5 |
AMG 548 | P38α inhibitor,potent and selective | 864249-60-5 |
Asiatic acid | Used in wound healing;anti-inflammatory | 464-92-6 |
BIRB 796 (Doramapimod) | P38 MAPK inhibitor,cell permeable and highly selective | 285983-48-4 |
CMPD-1 | 41179-33-3 | |
DBM 1285 dihydrochloride | ||
EO 1428 | 321351-00-2 | |
JX 401 | 349087-34-9 | |
Losmapimod | 585543-15-3 | |
LY2228820 | P38 MAP kinase inhibitor | 862507-23-1 |
PD 169316 | P38 MAPK inhibitor | 152121-53-4 |
Pexmetinib (ARRY-614) | dual inhibitor of p38 MAPK and Tie2/Tek receptor tyrosine kinase | 945614-12-0 |
PH-797804 | P38 MAP kinase inhibitor, potent and selective | 586379-66-0 |
Piperine | MAPK inhibitor | 94-62-2 |
SB 203580 | P38 MAP kinase inhibitor | 152121-47-6 |
SB 203580 hydrochloride | Specific p38-MAPKs inhibitor | 869185-85-3 |
SB 239063 | P38 MAP kinase inhibitor | 193551-21-2 |
SB 706504 | 911110-38-8 | |
SB202190 (FHPI) | P38 MAPK inhibitor | 152121-30-7 |
Skepinone-L | P38-MAPK inhibitor,potent and selective | 1221485-83-1 |
SKF 86002 dihydrochloride | 116339-68-5 | |
SX 011 | 309913-42-6 | |
TAK-715 | p38 MAPK inhibitor | 303162-79-0 |
VX-702 | P38α MAPK inhibitor,highly selective and ATP-competitive | 479543-46-9 |
VX-745 | P38α inhibitor,highly potent and selective | 209410-46-8 |